P29 is the core 29-peptide intermediate of Semaglutide (GLP1 (937), Arg34 mutation), and its global demand is fully bound to Semaglutide API and preparations:
Injectables (Ozempic/Wegovy): Global sales reached approximately 34.6 billion US dollars in 2025, with weight loss indications accounting for over 60%, driving P29 demand growth of over 35% annually.
Oral preparations (Rybelsus): Upgraded Amycretin advanced in 2026 with bioavailability increased to 8%, requiring higher P29 dosage per dose and bringing over 15% new demand increment.
Generic drug boom: China's compound patent expired in March 2026; more than 10 pharmaceutical enterprises submitted listing applications, and generic drugs will be released globally in 2027, driving another over 40% growth in P29 demand.
Regional differentiation: Europe and America enjoy priority supply with tightened allocation in Asia-Pacific and Latin America; the Middle East, India and Southeast Asia become new growth poles for generic drugs.
One-sentence summary: Booming weight loss rigid demand, new increment from oral preparations, generic drugs magnify market demand; global supply shortage and uneven regional allocation.
Original Research (Novo Nordisk): 100% self-produced P29/API; annual capacity of 1.5–2 tons at Kalundborg base in Denmark, prioritized for self-owned preparations with minimal external sales and quotation ≥3,000 US dollars/gram.
Chinese Manufacturers (Main Force): Account for 60–70% of global P29 supply, divided into two echelons:
High-end high-purity grade (≥99.5%, USP/EP grade): Nuotai, Shengnuo, WuXi AppTec with annual capacity of 10–15 tons, priced at 800–1,500 US dollars/gram, supplying European and American regulated markets.
Mid-to-low-end grade (98–99%, industrial grade): Over 20 small and medium-sized manufacturers with overcapacity, priced at 200–500 US dollars/gram, supplying unregulated markets (compounding pharmacies, Southeast Asia, Middle East).
Overseas Capacity: Small-scale layout by South Korea (LG Chem), India (Dr. Reddy’s) and Europe (Lonza), to be released after 2027, unable to shake the market pattern in the short term.
One-sentence summary: Original research controls high-end market, domestic manufacturers divided into two tiers; high-purity products gain premium profits, low-end market trapped in price wars.
Purity Threshold: Regulated markets (FDA/EMA) mandate ≥99.5% purity with single impurity ≤0.1%; original research standard ≥99.9%; impurities such as deleted peptides and oxidized peptides directly affect efficacy and safety.
Key Quality Control Items: Amino acid sequence, mass spectrometry, HPLC, moisture ≤50ppm, endotoxin ≤0.1EU/mg, biological activity ≥95%, all indispensable.
Process Upgrading: Transition from Solid Phase Peptide Synthesis (SPPS) to solid-liquid integration + enzymatic catalysis; yield increased from 30% to 60% with a 40% cost reduction; automated continuous production becomes standard configuration.
Compliance Barriers: FDA DMF, CEP, GMP, batch traceability and audit trail become market access thresholds, unattainable for small and medium-sized manufacturers.
One-sentence summary: Purity determines survival, impurities determine price, compliance determines market access; technology and quality control serve as core barriers.
High-end high-purity grade (≥99.5%): Tight supply and certification barriers keep prices firm at 800–1,500 US dollars/gram with gross profit margins of 50–60%.
Mid-to-low-end grade (98–99%): Overcapacity and price wars drive prices down from 1,000 to 200 US dollars/gram in 2025–2026 with gross profit margins of 5–10%, forcing small and medium-sized manufacturers into losses and exit.
Core Costs: Fmoc amino acids, condensing reagents (HATU), resin and energy account for 70% of total costs; raw material prices rose by 30–50% in 2025, squeezing low-end profit margins.
Regional Price Gaps: Europe > North America > Japan-South Korea > Domestic China > India/Southeast Asia, creating significant global price comparison arbitrage space.
One-sentence summary: High-end high profit margins, low-end market losses; costs rise upstream while prices decline downstream, leading to intensified differentiation.
European and American buyers reduce reliance on China: Certify Novo Nordisk (original research), South Korea, India and European capacity simultaneously to build 2–3 supply sources and avoid geopolitical and quality risks.
Leading Chinese enterprises go global: Nuotai and Shengnuo set up warehouses/factories in Southeast Asia and Mexico to serve global customers and reduce tariff and compliance risks.
Combination of long-term contracts and spot goods: Lock 70–80% of consumption via 1–2 year long-term contracts to secure high-purity capacity and prices, and purchase the remaining 20–30% via spot transactions for flexible inventory replenishment amid market fluctuations.
Technology service binding: High-end buyers demand formula collaboration, impurity spectrum analysis, stability testing and GMP audit support; pure product sales face survival pressure.
One-sentence summary: Safety first, diversified sourcing dominates, technology binding and regional layout prevail; supply chain shifts from cost orientation to resilience and technology orientation.
HiSiaddi divides downstream buyers into four typical categories covering mainstream global downstream clients:
European and American regulated market pharmaceutical giants (original research + generic drugs, FDA/EMA)
Chinese generic pharmaceutical enterprises (CDE approval, patent expiration in 2026)
Southeast Asia/Middle East/Indian generic pharmaceutical enterprises (unregulated + semi-regulated markets)
Global CDMO/Contract Development & Manufacturing Organizations (OEM for API/preparations)
Challenges
Global shortage of high-purity P29 (≥99.5%, USP/EP grade), capacity controlled by original research; leading Chinese capacity prioritized for long-term contracts with delivery cycles of 8–12 weeks and high prices.
Extremely high certification thresholds: FDA DMF, CEP, GMP, on-site audit, full impurity spectrum and biological activity testing, unattainable for small and medium-sized suppliers.
Zero-tolerance quality control: Batch fluctuations, excessive impurities or insufficient biological activity will lead to full-batch scrappage with huge losses; European and American regulatory supervision tightens with increased sampling frequency.
Supply chain safety: Geopolitical risks and concentrated Chinese capacity bring high single-source reliance risks, creating urgent demand for diversified backup suppliers.
Opportunities
Global Semaglutide demand booms with Europe and America as the core market; high-purity P29 demand grows by over 35% annually with strong long-term certainty.
Limited original research capacity prioritized for self-use; European and American customers actively seek second-source suppliers outside original research, creating a golden window for leading Chinese high-purity suppliers (Nuotai, Shengnuo).
High premium after certification: Prices stabilize at 800–1,500 US dollars/gram after passing FDA/EMA certification with gross profit margins of 50–60%, accompanied by stable orders and favorable account terms.
Long-term cooperation via technology binding: Jointly develop exclusive impurity control schemes and stability optimization to lock priority supply rights for 2–3 years and secure production capacity and technological advantages.
Challenges
Tight high-purity P29 capacity; leading suppliers prioritize supply to European and American long-term contracts with limited domestic allocation and high prices (600–1,000 US dollars/gram).
Imminent price war: Over 10 enterprises will compete after patent expiration in 2026; preparation prices may drop to 30–50% of original research prices, forcing P29 cost reduction.
Tightening CDE quality control: Mandate purity ≥99.5%, single impurity ≤0.1%, full impurity spectrum and biological activity & GMP compliance; strict approval with direct rejection for unqualified quality.
Lagging capacity expansion: Construction cycle of domestic high-purity capacity lasts 18–24 months, unable to meet surging short-term demand.
Opportunities
Local supply advantage: China is the global main production base of P29 with sufficient spot supply, short delivery cycles (2–4 weeks) and convenient communication, more flexible than European and American procurement.
Obvious cost advantage: Domestic high-purity P29 is 30–50% cheaper than imported products, supporting preparation price wars and rapid market share expansion.
Golden window for rapid volume release: 2026–2027 is the golden period for domestic generic drug volume release; enterprises obtaining early approval and stable supply can seize 20–30% market share.
Overseas expansion potential: After domestic capacity surplus, high-quality domestic P29 can be exported to Southeast Asia, Middle East and Latin America to expand global market increment.
Challenges
Uneven product quality: Flooded with 98–99% industrial grade P29 in the market with large batch fluctuations, excessive impurities and insufficient activity, leading to poor preparation efficacy, side effects and high return rates.
Low compliance threshold but rampant counterfeits: Unregulated markets exempt from FDA/CEP certification only require COA; low-price counterfeits (purity <95%) run rampant with brutal price wars and thin profit margins.
Chaotic supply and unstable delivery: Numerous small and medium-sized suppliers with scattered capacity lead to frequent supply disruption, delivery delay and adulteration, affecting production plans.
Terminal price sensitivity: Low local purchasing power mandates preparation prices below 70% of original research prices, forcing P29 prices down to 200–500 US dollars/gram.
Opportunities
Strong rigid demand and huge market scale: Large and fast-growing diabetic and obese population in Southeast Asia, Middle East and India drives low-cost generic drug demand growth of over 40% annually.
Mid-to-low-end domestic P29 well-matched: Chinese small and medium-sized manufacturers’ 98–99% industrial grade P29 features low prices and sufficient supply, perfectly matching local low-cost and fast-shipment demand.
Decent profit margins and fast capital flow: Despite low unit prices, large order volumes, good cash flow and short account terms (cash/30 days) bring gross profit margins of 10–15% via small profits but quick turnover.
Regional deep cultivation barriers: Establish stable cooperation with 2–3 suppliers, strictly control incoming material quality inspection and provide low-cost preparation formula support to form regional competitive barriers.
Challenges
High technical threshold: CDMO requires full-chain capabilities including P29 synthesis, API purification, preparation development, quality control and GMP compliance; customized production of high-purity P29 features high difficulty, low yield and high costs.
Strict quality control and major liability risks: As an OEM manufacturer, P29 quality directly affects final preparations with joint liability risks; quality inspection standards are consistent with pharmaceutical giants.
Multiple customized demands and small batches: Different customers have distinct requirements for specifications, purity and impurities, demanding flexible production and fast switching capabilities with weak scale effects.
Price sensitivity and fierce competition: Intense competition in the CDMO industry leads to obvious customer price pressure; P29 costs account for 60–70% of API costs, squeezing gross profit margins.
Opportunities
High added value of one-stop service: Provide full-process OEM services from P29 to API to preparations with a 15–20% premium and strong customer stickiness and repeat purchase rates.
Bind leading preparation customers: Serve European and American regulated market pharmaceutical giants and leading Chinese generic pharmaceutical enterprises with stable large orders and favorable payment terms, avoiding risks from small and low-quality customers.
Technological moat barriers: Master core technologies of high-purity P29 synthesis, impurity control and stability optimization, difficult for competitors to replicate and forming differentiated barriers.
Global capacity layout: Set up factories in China (cost advantage), Southeast Asia (tariff avoidance) and Europe/America (proximity to customers) to supply P29/API/preparations locally, reduce logistics costs, avoid tariffs and enhance global competitiveness.
Lock high-purity capacity 12 months in advance: Sign exclusive long-term contracts with 1 leading Chinese supplier (Nuotai/Shengnuo) + 1 original research/South Korean supplier to secure ≥99.5% high-purity P29 and guarantee delivery cycles (8–12 weeks) and quality.
Enforce strict certification and on-site audit: Require suppliers to provide FDA DMF, CEP, GMP, full impurity spectrum and biological activity reports, conduct quarterly on-site audits and eliminate unqualified suppliers immediately.
Strict parameter control with zero tolerance: Only accept products with purity ≥99.5%, single impurity ≤0.1%, moisture ≤50ppm, endotoxin ≤0.1EU/mg and biological activity ≥95%; fully return and claim compensation for unqualified batches.
Place local safety inventory in advance: Reserve 90-day consumption in European and American bonded warehouses to cope with delivery delays, sudden demand surges and supply chain disruption risks.
Carry out technology binding and joint R&D: Jointly develop exclusive impurity control schemes and stability optimization with suppliers to lock priority supply rights for 2–3 years and secure production capacity and technological advantages.
Prioritize locking local high-purity capacity: Sign long-term contracts with Nuotai, Shengnuo and WuXi AppTec 6–12 months in advance to secure ≥99.5% high-purity P29 and avoid capacity seizure by European and American customers.
Conduct global price comparison and cost hedging: Inquire about high-purity P29 quotes from China, South Korea and India simultaneously to reduce costs via regional price gaps; lock 70% of prices via long-term contracts and purchase 30% via spot transactions for flexible inventory replenishment to cope with price fluctuations.
Accelerate CDE certification progress: Require suppliers to provide complete impurity spectrum, biological activity, stability data and GMP documents for pre-review in advance to seize the first batch approval window after patent expiration in 2026.
Strict incoming material quality inspection and batch stability: Establish an independent quality inspection laboratory to test purity, impurities, moisture, endotoxin and biological activity for each batch; reject unqualified products firmly to avoid impacting approval and market launch.
Overseas layout in Southeast Asia/Middle East: Amid fierce domestic market competition, export high-quality domestic P29 and preparations to Southeast Asia, Middle East and Latin America relying on cost advantages to expand global incremental markets.
Lock cooperation with 2–3 stable mid-to-low-end suppliers: Select 2–3 reputable and capacity-stable Chinese mid-to-low-end manufacturers, sign 6–12 month long-term contracts to ensure stable supply of 98–99% industrial grade P29 and avoid supply disruption and counterfeit products.
Establish simple but strict quality inspection procedures: Sampling inspection of purity, major impurities and activity for each batch; firmly return products with purity <98% or activity <90% to control preparation quality risks and reduce return rates.
Conduct global price comparison to minimize costs: Inquire about mid-to-low-end P29 quotes from China, India and Southeast Asia simultaneously to push prices down to 200–300 US dollars/gram and adopt small profits but quick turnover to adapt to price-sensitive local markets.
Deepen regional cultivation and bind technical services: Target conventional preparation specifications (0.5mg/1mg) in local markets, require suppliers to provide low-cost formula support, process optimization and basic quality control training to form regional barriers and reduce price wars.
Firmly reject counterfeits and maintain reputation: Refuse ultra-low-priced counterfeit products with purity <95%; prefer purchasing genuine products at a moderate price over cheap counterfeits to safeguard terminal reputation and avoid long-term customer loss.
Upgrade technology and master core high-purity technologies: Invest in R&D of solid-liquid integration + enzymatic catalysis processes to raise P29 yield to 50–60% and reduce costs by 30–40%; overcome core technologies of impurity control and stability optimization to form differentiated barriers.
Build full-chain capabilities from P29 to API to preparations: Compensate shortcomings in P29 synthesis, API purification, preparation development, quality control and GMP compliance, provide one-stop OEM services to increase added value (15–20% premium) and customer stickiness.
Implement customer hierarchy management and focus on leading clients: Prioritize serving European and American regulated market pharmaceutical giants and leading Chinese generic pharmaceutical enterprises with stable large orders and favorable payment terms; eliminate small and low-quality customers to reduce risks and resource waste.
Build flexible production for fast switching: Construct multi-specification, small-batch and fast-switching flexible production lines to meet customized purity, impurity and specification demands of different customers and enhance order undertaking capacity.
Deploy global production capacity for local service: Set up factories in China (cost advantage), Southeast Asia (tariff avoidance) and Europe/America (proximity to customers) to supply P29/API/preparations locally, reduce logistics costs, avoid tariffs and improve response speed.
+86-13120989737 
info@hisiaddi.com 
English
